Loading
companiesCompany
Neovii
Neovii is a Swiss company whose anti-T-lymphocyte globulin, Grafalon, is given before stem cell transplants to lower the risk of graft versus host disease.
Also called: Neovii BiotechNeovii Biotech GmbHNeovii Pharmaceuticals AG
Overview
Neovii, headquartered in Rapperswil-Jona, Switzerland, makes Grafalon (anti-T-lymphocyte globulin, previously ATG-Fresenius), a rabbit-derived polyclonal antibody used in conditioning before allogeneic haematopoietic stem cell transplantation to reduce graft versus host disease and rejection. It has led phase 3 transplant trials in leukaemia registered on ClinicalTrials.gov.
Similar pages
- TreatmentCatumaxomab
Shares Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian Cancer, Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy.
- PersonXiaojun Huang
Shares Allogeneic stem cell transplant (allo-SCT), Acute lymphoblastic leukaemia, Acute myeloid leukaemia.
- PersonJohn F. DiPersio
Shares Allogeneic stem cell transplantation, Acute lymphoblastic leukaemia, Acute myeloid leukaemia.
- TreatmentOmidubicel
Shares Allogeneic stem cell transplantation, Acute lymphoblastic leukaemia, Acute myeloid leukaemia.
- TargetCD7
Shares Allogeneic stem cell transplantation, Acute lymphoblastic leukaemia, Acute myeloid leukaemia.
- TreatmentDorocubicel (UM171-expanded cord blood)
Shares Allogeneic stem cell transplantation, Acute lymphoblastic leukaemia, Acute myeloid leukaemia.
- CompanyBellicum Pharmaceuticals
Shares Allogeneic stem cell transplantation, Acute lymphoblastic leukaemia, Acute myeloid leukaemia.
- TreatmentAllogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq
Shares Allogeneic stem cell transplantation, Acute lymphoblastic leukaemia, Acute myeloid leukaemia.